Kane Biotech Q2 FY26 net loss widens to $(833,636); revenue drops 70.92% to $8,143

• Kane Biotech Q2 2026 revenue fell 70.92% to $8,143 as it continued early-stage commercialization of the revyve product line.
• Net loss widened to $(833,636) from $(348,541), driven primarily by higher operating expenses.
• Operating expenses climbed to $785,927 from $229,930, on stock option expense and the absence of prior-period compensation accrual reversals.
• Gross profit swung to $1,444 from a gross loss of $(45,526) as revyve sales began contributing positive gross margin.
• Cash totaled $854,729 at June 30, 2026; management cited expanded distribution, added financing, and a strategic review to support growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kane Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608271705PRIMZONEFULLFEED9817090) on August 27, 2026, and is solely responsible for the information contained therein.